ibs-smart™️ is an ELISA blood test that measures the levels of two antibodies known to be elevated in patients with post-infectious irritable bowel syndrome (IBS).
The test offers physicians an optimized diagnosis protocol for diarrhea-predominant and mixed-type irritable bowel syndrome (IBS-D and IBS-M).
For the 10-15% of the worldwide population that suffers from IBS, ibs-smart™️ can offer a clear diagnosis, prevent potentially unnecessary invasive procedures, and set a faster path to treatment.
The test is based on a 2,500-patient study conducted at Cedars-Sinai Medical Center. Gemelli Biotech has the exclusive license from Cedars-Sinai to bring this test to market and continues to innovate the test in alignment with ongoing research into the pathophysiology of IBS.
To learn more, visit: www.ibssmart.com
IS THE SECOND-
GENERATION BLOOD TEST FOR IBS
sclero-smart™️ measures the levels of an antibody, anti-vinculin, that is elevated in up to 38% of patients with systemic sclerosis and scleroderma. This prevalence is higher than that of any other marker commonly used in the diagnosis of scleroderma.
Elevated levels of anti-vinculin are also predictive of pulmonary hypertension and gastrointestinal complications. No other marker currently available is reliable in predicting the involvement of the GI system.
The connection between anti-vinculin and scleroderma also suggests that the gut microbiome could hold the key to new diagnostic and therapeutic tools for scleroderma.
To learn more, visit: www.sclerosmart.com
AIDS IN THE DIAGNOSIS OF SCLERODERMA